Search
CX-046684
go.drugbank.com/drugs/DB19414ApprovedCX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.
Lortalamine
go.drugbank.com/drugs/DB09187ExperimentalThis drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters. … Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s.
Tiazofurine
go.drugbank.com/drugs/DB13243ExperimentalTiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase [A174991].
Atl146e
go.drugbank.com/drugs/DB05191InvestigationalATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Zolasartan
go.drugbank.com/drugs/DB20140ExperimentalZolasartan has a monoisotopic molecular weight of 554.05 Da. … The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Categories: Agents Acting on the Renin-Angiotensin SystemKaraya gum
go.drugbank.com/drugs/DB10535ApprovedKaraya gum allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingJosamycin
go.drugbank.com/drugs/DB01321InvestigationalThe drug has antimicrobial activity against a wide spectrum of pathogens.
Camellia japonica seed oil
go.drugbank.com/drugs/DB14308InvestigationalCamellia japonica seed oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Nail Care PenBufogenin
go.drugbank.com/drugs/DB19835ExperimentalBufogenin has a monoisotopic molecular weight of 384.23 Da.
Categories: Compounds used in a research, industrial, or household settingInbakicept
go.drugbank.com/drugs/DB16479Investigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components.
Synonyms: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN